Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Yellow Nail Syndrome | 1 | 2018 | 2 | 0.670 |
Why?
|
| Pleurodesis | 1 | 2018 | 41 | 0.650 |
Why?
|
| Chylothorax | 1 | 2018 | 84 | 0.620 |
Why?
|
| Myocarditis | 2 | 2022 | 768 | 0.560 |
Why?
|
| Problem-Based Learning | 1 | 2019 | 361 | 0.510 |
Why?
|
| Calorimetry, Indirect | 1 | 2014 | 183 | 0.460 |
Why?
|
| Cardiovascular System | 1 | 2020 | 828 | 0.440 |
Why?
|
| Clinical Competence | 2 | 2019 | 4687 | 0.400 |
Why?
|
| Teaching | 1 | 2019 | 1173 | 0.380 |
Why?
|
| Actigraphy | 1 | 2014 | 488 | 0.360 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2019 | 1007 | 0.350 |
Why?
|
| Coronary Artery Bypass | 1 | 2018 | 2288 | 0.330 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 13112 | 0.300 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 1738 | 0.280 |
Why?
|
| Students, Medical | 1 | 2019 | 1862 | 0.270 |
Why?
|
| Energy Metabolism | 2 | 2017 | 2899 | 0.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5230 | 0.230 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 3229 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11524 | 0.180 |
Why?
|
| Neoplasms | 4 | 2024 | 21675 | 0.180 |
Why?
|
| Breast Neoplasms | 7 | 2017 | 20827 | 0.160 |
Why?
|
| Thoracic Duct | 1 | 2018 | 63 | 0.160 |
Why?
|
| Talc | 1 | 2018 | 47 | 0.160 |
Why?
|
| Fatigue | 2 | 2017 | 1530 | 0.160 |
Why?
|
| Chest Tubes | 1 | 2018 | 150 | 0.150 |
Why?
|
| Lymphography | 1 | 2018 | 201 | 0.150 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 13691 | 0.150 |
Why?
|
| Doxycycline | 1 | 2018 | 326 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 3 | 2017 | 2727 | 0.140 |
Why?
|
| Faculty | 1 | 2019 | 386 | 0.130 |
Why?
|
| Receptor, erbB-2 | 1 | 2022 | 2418 | 0.100 |
Why?
|
| Schools, Medical | 1 | 2019 | 879 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 2453 | 0.100 |
Why?
|
| Cyclophosphamide | 2 | 2017 | 2241 | 0.100 |
Why?
|
| Doxorubicin | 2 | 2017 | 2234 | 0.100 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2009 | 31 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 4552 | 0.080 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 11036 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2020 | 2789 | 0.070 |
Why?
|
| Humans | 18 | 2024 | 743811 | 0.070 |
Why?
|
| Neural Stem Cells | 1 | 2013 | 851 | 0.070 |
Why?
|
| Curriculum | 1 | 2019 | 3603 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 5532 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2009 | 1729 | 0.060 |
Why?
|
| Motor Activity | 1 | 2014 | 2714 | 0.060 |
Why?
|
| Education, Medical | 1 | 2016 | 1722 | 0.060 |
Why?
|
| Off-Label Use | 1 | 2024 | 169 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3134 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3241 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1832 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2016 | 8551 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 7172 | 0.050 |
Why?
|
| Anxiety | 1 | 2013 | 4288 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2013 | 4245 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 365 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 3480 | 0.040 |
Why?
|
| Depression | 2 | 2017 | 7760 | 0.040 |
Why?
|
| Middle Aged | 6 | 2018 | 213241 | 0.040 |
Why?
|
| Chemokine CCL3 | 1 | 2017 | 84 | 0.040 |
Why?
|
| Chemokine CCL11 | 1 | 2017 | 129 | 0.040 |
Why?
|
| Trail Making Test | 1 | 2017 | 57 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2019 | 53250 | 0.040 |
Why?
|
| Breast Diseases | 1 | 1999 | 443 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15281 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 1999 | 435 | 0.030 |
Why?
|
| Epitopes | 1 | 2022 | 2570 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2017 | 297 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 1836 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2017 | 577 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 1999 | 1639 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 620 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2022 | 77410 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2013 | 162 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2016 | 917 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 9272 | 0.030 |
Why?
|
| Premenopause | 1 | 2016 | 1033 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 8856 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2013 | 528 | 0.020 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2013 | 284 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2020 | 1631 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2013 | 349 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 1813 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2013 | 1342 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 300 | 0.020 |
Why?
|
| Female | 8 | 2017 | 380020 | 0.020 |
Why?
|
| California | 1 | 2012 | 1402 | 0.020 |
Why?
|
| Triglycerides | 1 | 2016 | 2453 | 0.020 |
Why?
|
| Postmenopause | 1 | 2016 | 2458 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2022 | 4437 | 0.020 |
Why?
|
| Linear Models | 1 | 2017 | 5952 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 13980 | 0.020 |
Why?
|
| Adult | 3 | 2017 | 213889 | 0.020 |
Why?
|
| Survivors | 1 | 2016 | 2291 | 0.020 |
Why?
|
| Self Report | 1 | 2017 | 3550 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 7324 | 0.020 |
Why?
|
| Lipids | 1 | 2016 | 3307 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 163178 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 16674 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 3778 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2017 | 6976 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2012 | 6356 | 0.010 |
Why?
|
| Male | 2 | 2018 | 349776 | 0.010 |
Why?
|
| Animals | 3 | 2022 | 168660 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2016 | 3863 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4749 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2016 | 6259 | 0.010 |
Why?
|
| Mice | 2 | 2022 | 81154 | 0.010 |
Why?
|
| Sleep | 1 | 2017 | 4619 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 4463 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8385 | 0.010 |
Why?
|
| Sex Factors | 1 | 2013 | 10394 | 0.010 |
Why?
|
| Palpation | 1 | 1999 | 167 | 0.010 |
Why?
|
| Prevalence | 1 | 2016 | 15211 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 12243 | 0.010 |
Why?
|
| Survival Rate | 1 | 2012 | 12786 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 12354 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 29777 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2013 | 11478 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29052 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1999 | 1098 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 39001 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5170 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 72252 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 57744 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 63042 | 0.000 |
Why?
|
| Adolescent | 1 | 2013 | 85729 | 0.000 |
Why?
|
| Time Factors | 1 | 1999 | 40038 | 0.000 |
Why?
|
Concepts
(127)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_